Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Kuros Biosciences AG       CH0325814116

KUROS BIOSCIENCES AG

SummaryChartsNewsCalendarCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Kuros announces results of rights offering – capital increase will be implemented

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/12/2018 | 01:05pm EDT

Kuros announces results of rights offering - capital increase will be implemented

Schlieren (Zurich), Switzerland, December 12, 2018 - Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the results of the rights offering, first announced on November 29, 2018, in which a total of 8,013,306 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00 each were offered to Kuros' existing shareholders at an offer price of CHF 2.50 per share.

At expiration of the rights exercise period on December 12, 2018, 12.00 noon CET, subscription rights for 2,769,608 new registered shares were validly exercised, representing 34.6% of the new registered shares offered. 5,243,698 new registered shares for which subscription rights were not exercised will be offered in the share placement to eligible institutional investors or others.

The capital increase is expected to be implemented as previously announced, since the number of shares subscribed in the rights offering together with certain hard commitments from existing and new investors to subscribe additional shares in the share placement exceed the minimum CHF 8 million gross proceeds, which the Company requires to progress commercialization of MagnetOs bone graft substitute in the U.S. and selected geographies in Europe.

Offered shares in respect of which subscription rights have not been exercised will be available for sale in a share placement that shall occur from December 12, 2018, after close of trading, to December 13, 2018, after close of trading (the "Share Placement Period"). In order to prevent speculative trading that might affect the share price adversely for each of the potential investors, depending on such investors' respective investment case, the Company requested for the suspension of trading in its securities listed on the SIX Swiss Exchange on December 13, 2018 (i.e. during the Share Placement Period), which has been approved by the SIX Swiss Exchange. A suspension of trading on December 13, 2018 will ensure equal treatment of all shareholders during the Share Placement Period.

The final number of new registered shares issued, and the gross proceeds raised via the capital increase will depend on, inter alia, the number of shares subscribed amongst existing and new equity investors. The final number of offered shares and gross proceeds from the rights offering and share placement will be announced on December 13, 2018 after market close. If CHF 16 million of gross proceeds are raised in the capital increase, the phase 2 clinical study of the Company's proprietary fibrin-PTH (KUR-113) product in spinal fusion can continue as planned as otherwise it will have to be delayed. The listing and first day of trading of the new registered shares on the SIX Swiss Exchange and the delivery of the new registered shares against payment of the offer price are expected to take place on December 18, 2018.




Provider
Channel
Contact
Tensid EQS Ltd., Switzerland
www.tensid.ch


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
marco@tensid.ch
+41 41 763 00 50
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on KUROS BIOSCIENCES AG
07/09Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution o..
GL
06/26Kuros Biosciences to propose adjustment of authorized and conditional capital..
TE
05/21Annual General Meeting of Kuros Biosciences approves certain resolutions
TE
04/11KUROS BIOSCIENCES : Enters Convertible Bond Financing Agreement For Up To CHF 5 ..
AQ
02/13KUROS BIOSCIENCES : SeaSpine and Kuros Biosciences sign bone graft agreement
AQ
02/13KUROS BIOSCIENCES : Signs Agreement to Supply SeaSpine with Bone Graft Incorpora..
AQ
02/11SEASPINE : Kuros Biosciences Signs Agreement to Supply SeaSpine with Bone Graft ..
AQ
2018KUROS BIOSCIENCES : raises $16m for bone-growth protein
AQ
2018KUROS BIOSCIENCES : Ends Transformational Year With First MagnetOs Sales, Lead C..
AQ
2018KUROS BIOSCIENCES : Announces Results of Rights Offering Capital Increase Will b..
AQ
More news
Chart KUROS BIOSCIENCES AG
Duration : Period :
Kuros Biosciences AG Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Joost D. de Bruijn Chief Executive Officer
Christian Martin Itin Chairman
Michael Grau Chief Financial Officer
Pascal Longlade Chief Technology Officer
Gerhard Ries Director
Sector and Competitors
1st jan.Capitalization (M$)
KUROS BIOSCIENCES AG3.91%26
GILEAD SCIENCES8.82%84 164
VERTEX PHARMACEUTICALS6.43%45 080
REGENERON PHARMACEUTICALS-20.16%31 857
SAREPTA THERAPEUTICS INC43.04%11 437
GENMAB9.70%11 148